Literature DB >> 31930084

Clinical value of postoperative sentinel lymph node biopsy.

Zhixian He1, Yi Zhou1, Feiran Wang1, Qian Xu1, Wei Zhang1, Xiaojian Ni2, Sujie Ni3.   

Abstract

BACKGROUND: This study analyzed the clinical data and general information of breast cancer patients who were admitted by the Affiliated Hospital of Nantong University and underwent lumpectomy, followed by sentinel lymph node biopsy (SLNB) to investigate the effect of tumor location on the sentinel lymph node (SLN) detection rate, obtain a clear understanding of the SLNB procedure and further promote the use of this procedure in the local area.
METHODS: This study involved a total of 118 patients who were diagnosed with breast cancer and admitted by the Affiliated Hospital of Nantong University for lumpectomy and SLNB between July 2015 and June 2019. An analysis was conducted to explore the role of tumor location in the detection of SLNs.
RESULTS: Tumor location was associated with the success rate of post-lumpectomy SLNB. In the case of tumor location in the upper outer quadrant (UOQ) of the breast near the axilla, the SLN detection rate was relatively low. In contrast, when a tumor occurred in any of the other quadrants or the UOQ next to the areola, the tumor location had no significant impact on the SLN detection rate. SLNB indicated that 102 out of the 118 patients had SLNs, with the detection rate of 86.4%. Particularly, for patients whose tumors were located in the UOQ near their axillae, the SLN detection rate was 30% (3/10). As to tumor location in other quadrants or the UOQ next to the areola, the SLN detection rate was up to 90.8% (99/109).
CONCLUSIONS: The performance of post-lumpectomy SLNB is associated with tumor location. SLNB is recommended when the tumor site lies in the upper inner/lower outer/lower inner quadrants (UIQ/LOQ/LIQ) of the breast or the UOQ next to the areola. If the SLNB result turns out to be negative, there is no need to perform axillary lymph node dissection (ALND). For tumor location in the UOQ of the breast, especially when it is near the axilla, SLNB is not a favorable option after lumpectomy. It is recommended that the patient receive a core needle biopsy (CNB) before SLNB. 2019 Annals of Translational Medicine. All rights reserved.

Entities:  

Keywords:  Breast cancer; post-lumpectomy; sentinel lymph node biopsy (SLNB)

Year:  2019        PMID: 31930084      PMCID: PMC6944544          DOI: 10.21037/atm.2019.11.106

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  21 in total

1.  Internal mammary sentinel lymph node biopsy in clinical practice.

Authors:  Mehdi Asadi; David Krag
Journal:  Int J Surg       Date:  2016-11-14       Impact factor: 6.071

Review 2.  Evolution in sentinel lymph node biopsy in breast cancer.

Authors:  Si-Qi Qiu; Guo-Jun Zhang; Liesbeth Jansen; Jakob de Vries; Carolien P Schröder; Elisabeth G E de Vries; Gooitzen M van Dam
Journal:  Crit Rev Oncol Hematol       Date:  2017-09-20       Impact factor: 6.312

3.  Axillary reverse mapping using 99mTc-SC: a case illustration.

Authors:  Sunny J Gandhi; C Satish; P Shanmuga Sundaram; Padma Subramanyam; D K Vijaykumar
Journal:  Clin Nucl Med       Date:  2014-10       Impact factor: 7.794

4.  Success in sentinel lymph node procedures in obese patients with breast cancer.

Authors:  Ute Gawlick; Mary C Mone; Edward T Nelson; Heidi J Hansen; Edward W Nelson
Journal:  Am J Surg       Date:  2010-12       Impact factor: 2.565

5.  Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial.

Authors:  Robert E Mansel; Lesley Fallowfield; Mark Kissin; Amit Goyal; Robert G Newcombe; J Michael Dixon; Constantinos Yiangou; Kieran Horgan; Nigel Bundred; Ian Monypenny; David England; Mark Sibbering; Tholkifl I Abdullah; Lester Barr; Utheshtra Chetty; Dudley H Sinnett; Anne Fleissig; Dayalan Clarke; Peter J Ell
Journal:  J Natl Cancer Inst       Date:  2006-05-03       Impact factor: 13.506

6.  Identification and Preservation of Arm Lymphatic System in Axillary Dissection for Breast Cancer to Reduce Arm Lymphedema Events: A Randomized Clinical Trial.

Authors:  Qianqian Yuan; Gaosong Wu; Shu-Yuan Xiao; Jinxuan Hou; Yuqi Ren; Hongying Wang; Kun Wang; Dan Zhang
Journal:  Ann Surg Oncol       Date:  2019-06-25       Impact factor: 5.344

Review 7.  Breast cancer: a review for the general surgeon.

Authors:  Cindy B Matsen; Leigh A Neumayer
Journal:  JAMA Surg       Date:  2013-10       Impact factor: 14.766

8.  Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update.

Authors:  Gary H Lyman; Sarah Temin; Stephen B Edge; Lisa A Newman; Roderick R Turner; Donald L Weaver; Al B Benson; Linda D Bosserman; Harold J Burstein; Hiram Cody; James Hayman; Cheryl L Perkins; Donald A Podoloff; Armando E Giuliano
Journal:  J Clin Oncol       Date:  2014-03-24       Impact factor: 44.544

9.  Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial.

Authors:  Armando E Giuliano; Karla Ballman; Linda McCall; Peter Beitsch; Pat W Whitworth; Peter Blumencranz; A Marilyn Leitch; Sukamal Saha; Monica Morrow; Kelly K Hunt
Journal:  Ann Surg       Date:  2016-09       Impact factor: 12.969

10.  Establishment and Verification of a Bagged-Trees-Based Model for Prediction of Sentinel Lymph Node Metastasis for Early Breast Cancer Patients.

Authors:  Chao Liu; Zeyin Zhao; Xi Gu; Lisha Sun; Guanglei Chen; Hao Zhang; Yanlin Jiang; Yixiao Zhang; Xiaoyu Cui; Caigang Liu
Journal:  Front Oncol       Date:  2019-04-16       Impact factor: 6.244

View more
  3 in total

1.  Comparison of indocyanine green fluorescence and methylene blue dye in the detection of sentinel lymph nodes in breast cancer.

Authors:  Zhenghui Wang; Yangyang Cui; Mingjie Zheng; Han Ge; Yue Huang; Jinghui Peng; Hui Xie; Shui Wang
Journal:  Gland Surg       Date:  2020-10

2.  Sentinel lymph node biopsy should be considered for clinically node-negative breast cancer regardless of BRCA1/2 mutation status.

Authors:  Xin Huang; Jia-Qi Liu; Yi-Dong Zhou; Ying Xu; Chang Chen; Xiang Wang; Xi Cao; Ru Yao; Qiang Sun
Journal:  Ann Transl Med       Date:  2020-09

3.  Erratum to clinical value of postoperative sentinel lymph node biopsy.

Authors:  Zhixian He; Yi Zhou; Feiran Wang; Qian Xu; Wei Zhang; Xiaojian Ni; Sujie Ni
Journal:  Ann Transl Med       Date:  2020-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.